Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail
-

Office of New Drugs Realignment: Applications

Realignment of current INDs, NDAs and BLAs

 

This list includes medical imaging applications that will be moving from the Division of medical imaging and Hematology Products to the new Division of medical imaging Products. Hematology applications residing in the Division of medical imaging and Hematology Products will remain in the Office of Oncology Drug Products in the new Division of Hematology Products.

Applications in the Division of Medical Imaging Products: (PDF - 578KB)

 

This list includes rheumatology applications that will be moving from the Division of Anesthesia, Analgesia, and Rheumatology Products to the new Division of Pulmonary, Allergy, and Rheumatology Products. Applications for products to treat the pain of rheumatological diseases, rather than to treat the underlying disease process, will remain in the Division of Anesthesia and Analgesia Products.

rheumatology applications in the Division of Pulmonary, Allergy, and Rheumatology Products: (PDF - 223KB)

 

If you believe your application number is listed in error and should not be transferred, or was omitted in error and should be transferred, please contact the appropriate individual listed below:
Division of Medical Imaging Products: Kaye Kang 301-796-2050
Division of Hematology Products: Janet Jamison 301-796-2313
Division of Anesthesia and Analgesia Products: 
Parinda Jani 301-796-1232 or Sara Stradley 301-796-1298
Division of Pulmonary, Allergy, and Rheumatology Products: Sandy Barnes 301-796-1174

 

 

-
-